| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | RACE |
| Entrez GeneID | 23600 |
| clone | 2A10F3 |
| WB Predicted band size | 42kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of human AMACR expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于AMACR(α-甲基酰基辅酶A消旋酶)抗体的3篇经典文献及其摘要概括：
1. **文献名称**：*α-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer*
**作者**：Jiang Z et al.
**摘要**：该研究首次提出AMACR作为前列腺癌特异性生物标志物，通过免疫组化分析显示AMACR在前列腺癌细胞中高度表达，而在良性组织中表达缺失，提示其在前列腺癌诊断中的潜在价值。
2. **文献名称**：*Utilization of AMACR Immunohistochemistry in the Diagnosis of Prostatic Carcinoma*
**作者**：Rubin MA et al.
**摘要**：研究验证了AMACR抗体在鉴别前列腺癌与良性增生中的敏感性和特异性，表明联合使用AMACR与基底细胞标记物(如p63)可提高病理诊断的准确性。
3. **文献名称**：*AMACR Expression in Colorectal Cancer: Correlation with Tumor Progression*
**作者**：Evans AJ et al.
**摘要**：该文献扩展了AMACR的应用范围，发现其在结直肠癌中表达上调，并与肿瘤分化程度和转移风险相关，提示AMACR可能作为多种癌症的预后评估指标。
4. **文献名称**：*AMACR Overexpression in Hepatocellular Carcinoma: Implications for Diagnosis*
**作者**：Zhou M et al.
**摘要**：研究报道AMACR在肝细胞癌中的异常表达，提出其可作为肝癌鉴别诊断的辅助标志物，尤其在区分高分化肝癌与良性肝病变中具有临床应用价值。
以上文献均聚焦AMACR的肿瘤特异性表达及其在病理诊断中的作用，覆盖前列腺癌、结直肠癌和肝癌等多个领域。
Alpha-methylacyl-CoA racemase (AMACR), also known as P504S, is a mitochondrial and peroxisomal enzyme involved in lipid metabolism, particularly the β-oxidation of branched-chain fatty acids and bile acid intermediates. Its gene, located on chromosome 5p13. encodes a protein that catalyzes the conversion of (2R)-methyl-branched fatty acyl-CoA esters to their (2S)-stereoisomers, a critical step in energy production pathways.
AMACR gained prominence in oncology due to its overexpression in various cancers, most notably prostate adenocarcinoma. Studies in the early 2000s identified AMACR as a sensitive immunohistochemical marker for prostate cancer diagnosis, helping distinguish malignant glands from benign proliferative lesions in biopsy specimens. This discovery addressed a persistent diagnostic challenge in pathology practice.
Beyond prostate cancer, AMACR overexpression has been documented in colorectal carcinomas, renal cell carcinomas, and some ovarian cancers. The antibody against AMACR is routinely used in diagnostic panels alongside basal cell markers (e.g., p63. 34βE12) to improve the accuracy of prostate cancer detection. Its expression pattern also shows potential for monitoring disease progression and treatment response.
Interestingly, AMACR's metabolic role links it to inherited disorders like adult-onset sensorimotor neuropathy and retinitis pigmentosa when mutated. However, in cancer contexts, the mechanisms driving its overexpression remain under investigation, with hypotheses ranging from metabolic reprogramming to androgen receptor pathway interactions. While primarily a diagnostic tool, ongoing research explores AMACR's therapeutic targeting potential in malignancies dependent on its metabolic functions.
×
